$13.15
-0.33(-2.45%)
Mkt Cap $503M
$5.02
$13.50
52-Week Range
At A Glance
1
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.
2
Revenue is primarily driven by Deferred Revenue At Inception (52.5%) and Recognition Of Upfront And Milestone Payments (38.6%).
3
Most recently: Results of Operations and Financial Condition. On February 26, 2026, Entrada Therapeutics, Inc. announced its financial results for the quarter ended December 3 (2026-02-26).
$503M
Market Cap
$24M
Revenue
-$133M
Net Income
Employees183
Fundamentals
How The Business Makes Money
Revenue by Segment
Deferred Revenue At Inception52.5%($124M)
Recognition Of Upfront And Milestone Payments38.6%($91M)
Collaboration Service Revenue8.9%($21M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001689375
ISINUS29384C1080
CUSIP29384C108
Phone857 520 9158
Address6 Tide Street, Boston, MA, 02210, US
SEC EDGAR